Implicit Licenses Clinical Stage Antibody Program From Lilly
Implicit Bioscience Ltd (Brisbane, Australia) has acquired the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company (Indianapolis, Indiana). Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive a royalty on future IC14 sales.
Implicit Bioscience Ltd (Brisbane, Australia) has acquired the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company (Indianapolis, Indiana). Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive a royalty on future IC14 sales.
Implicit intends to initiate Phase 2 clinical development in acute lung injury (ALI) during 2009. IC14 was originally being developed for severe sepsis at Icos Corporation, which was acquired by Lilly in 2007.
IC14 is a clinical stage recombinant chimeric monoclonal antibody that recognizes and blocks the function of human CD14, an essential component of the innate inflammatory response to bacterial infection. CD14 triggers activation of the innate immune response to bacterial components, including lipopolysaccharide, through the Toll-like receptor (TLR) pathway. Lung inflammation in response to innate immune activation through the TLR pathway is a primary factor in the early pathogenesis of ALI.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
